UBS AM’s Globus Medical GMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.8M Sell
250,823
-6,715
-3% -$571K ﹤0.01% 946
2026
Q1
$22.2M Buy
257,538
+12,843
+5% +$1.15M ﹤0.01% 844
2025
Q4
$21.4M Sell
244,695
-6,832
-3% -$519K ﹤0.01% 826
2025
Q3
$14.4M Sell
251,527
-229,545
-48% -$13.2M ﹤0.01% 950
2025
Q2
$28.4M Buy
481,072
+133,545
+38% +$8.63M 0.01% 905
2025
Q1
$25.4M Buy
347,527
+28,027
+9% +$2.32M 0.01% 860
2024
Q4
$26.4M Buy
319,500
+28,330
+10% +$2.23M 0.01% 845
2024
Q3
$20.8M Buy
291,170
+3,584
+1% +$253K 0.01% 935
2024
Q2
$19.7M Buy
287,586
+117,352
+69% +$7.01M 0.01% 868
2024
Q1
$9.13M Sell
170,234
-3,942
-2% -$212K ﹤0.01% 1036
2023
Q4
$9.28M Sell
174,176
-7,814
-4% -$381K ﹤0.01% 1013
2023
Q3
$9.04M Buy
181,990
+68,513
+60% +$3.83M ﹤0.01% 990
2023
Q2
$6.43M Hold
113,477
﹤0.01% 1127
2023
Q1
$6.43M Sell
113,477
-7,450
-6% -$478K ﹤0.01% 1127
2022
Q4
$8.98M Buy
120,927
+3,934
+3% +$268K ﹤0.01% 980
2022
Q3
$6.97M Sell
116,993
-26,398
-18% -$1.59M ﹤0.01% 1088
2022
Q2
$8.05M Buy
143,391
+17,582
+14% +$1.16M ﹤0.01% 1049
2022
Q1
$9.28M Sell
125,809
-7,170
-5% -$498K ﹤0.01% 1097
2021
Q4
$9.6M Sell
132,979
-231
-0.2% -$16.8K ﹤0.01% 1143
2021
Q3
$10.2M Sell
133,210
-3,191
-2% -$256K ﹤0.01% 1089
2021
Q2
$10.6M Buy
136,401
+6,437
+5% +$458K ﹤0.01% 1101
2021
Q1
$8.01M Sell
129,964
-7,876
-6% -$499K ﹤0.01% 1152
2020
Q4
$8.99M Buy
137,840
+9,651
+8% +$555K ﹤0.01% 1096
2020
Q3
$6.35M Buy
128,189
+9,418
+8% +$486K ﹤0.01% 1074
2020
Q2
$5.67M Sell
118,771
-9,887
-8% -$477K ﹤0.01% 1070
2020
Q1
$5.47M Sell
128,658
-4,302
-3% -$213K ﹤0.01% 1025
2019
Q4
$7.83M Sell
132,960
-23,938
-15% -$1.3M ﹤0.01% 1032
2019
Q3
$8.02M Buy
156,898
+10,138
+7% +$483K 0.01% 1037
2019
Q2
$6.21M Sell
146,760
-70,991
-33% -$3.08M ﹤0.01% 1120
2019
Q1
$10.8M Buy
217,751
+2,239
+1% +$101K 0.01% 911
2018
Q4
$9.33M Sell
215,512
-2,830
-1% -$141K 0.01% 897
2018
Q3
$12.4M Sell
218,342
-362
-0.2% -$19.1K 0.01% 877
2018
Q2
$11M Sell
218,704
-2,989
-1% -$156K 0.01% 924
2018
Q1
$11M Sell
221,693
-642
-0.3% -$30.2K 0.01% 912
2017
Q4
$9.14M Buy
222,335
+15,844
+8% +$555K 0.01% 940
2017
Q3
$6.14M Sell
206,491
-165
-0.1% -$5.04K 0.01% 1019
2017
Q2
$6.85M Buy
206,656
+5,021
+2% +$158K 0.01% 964
2017
Q1
$5.97M Buy
201,635
+46,857
+30% +$1.28M 0.01% 989
2016
Q4
$3.84M Buy
154,778
+30,756
+25% +$699K ﹤0.01% 1052
2016
Q3
$2.8M Buy
124,022
+16,430
+15% +$386K ﹤0.01% 1252
2016
Q2
$2.56M Sell
107,592
-2,925
-3% -$70.2K ﹤0.01% 1265
2016
Q1
$2.63M Buy
110,517
+19,836
+22% +$485K ﹤0.01% 1248
2015
Q4
$2.52M Buy
90,681
+46,820
+107% +$1.18M ﹤0.01% 1336
2015
Q3
$906K Buy
43,861
+10,300
+31% +$261K ﹤0.01% 1762
2015
Q2
$862K Buy
33,561
+12,261
+58% +$310K ﹤0.01% 1750
2015
Q1
$538K Buy
21,300
+900
+4% +$21.9K ﹤0.01% 1941
2014
Q4
$485K Buy
20,400
+1,700
+9% +$37.6K ﹤0.01% 1960
2014
Q3
$368K Hold
18,700
﹤0.01% 2029
2014
Q2
$447K Buy
18,700
+1,100
+6% +$26.5K ﹤0.01% 1956
2014
Q1
$468K Buy
17,600
+100
+0.6% +$2.38K ﹤0.01% 1936
2013
Q4
$353K Buy
17,500
+1,200
+7% +$22.3K ﹤0.01% 2017
2013
Q3
$285K Hold
16,300
﹤0.01% 2117
2013
Q2
$275K Buy
+16,300
New +$252K ﹤0.01% 2044

Other funds holding GMED

UBS AM's GMED Position: Q2 2026 in Review

UBS AM reduced its Globus Medical (GMED) stake by 2.6% in Q2 2026, selling an estimated $571K and leaving 250,823 shares worth $19.8M. The position accounts for ﹤0.01% of the portfolio, ranked #946.

UBS AM first reported a position in GMED in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.4M in Q2 2025. 594 funds tracked by Wall St. Rank hold GMED as of Q2 2026.

  • UBS AM held 250,823 shares of Globus Medical worth $19.8M as of Q2 2026.
  • UBS AM sold 6,715 Globus Medical shares in Q2 2026, an estimated $571K.
  • Globus Medical made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #946 holding.
  • UBS AM first reported a position in Globus Medical in Q2 2013 and has held it in 53 quarters since.
  • UBS AM's Globus Medical position peaked at $28.4M in Q2 2025.
  • 594 funds tracked by Wall St. Rank held Globus Medical as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.